A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
| Share Statistics | CTXR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11.1 | $464.0 | 8% |
|
| Shares Out (Mil) | 26.2 | 42.7 | 35% |
|
| Institutional Ownership | 73.4% | 82.2% | 45% |
|
| Float (Mil) | 27.0 | 44.3 | 33% |
|
| Beta | 0.99 | 0.73 | 59% |
|
| Avg Daily Volume (000s) | 288 | 292 | 50% |
|
| Price Change (52-week) |
(74.3%) | 55.0% | 11% |
|
| Growth | CTXR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (16.4%) | (2.4%) | 24% |
|
| EPS (5yr) | 21.3% | 14.9% | 70 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (52.7%) | (15.1%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.410) | ($2.030) | ($1.440) | |
| Month Ago EPS | ($0.410) | ($2.030) | ($1.440) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.250) | ($1.870) | ($0.810) | |
| Year/Year Chg | 20.9% | (40.0%) | (80.2%) | |
| Financials | CTXR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $416 | 7% |
|
| Net Income (TTM) (Mil) | ($46) | ($11) | 17% |
|
| EPS (TTM) | ($2.122) | ($0.700) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($35) | ($7) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $11 | $5 | 57% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $6 | 27% |
|
| Enterprise Value (Q1) (Mil) | $16 | $493 | 10% |
|
| Valuation | CTXR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.17 | 2.09 | 3% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | CTXR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 77.3% | 69.4% | 87% |
|
| Net Margin | (651.3%) | 3.2% | 1% |
|
| ROA | (34.3%) | (22.2%) | 15% |
|
| ROE | (70.3%) | (21.0%) | 12% |
|
| Liabilities to Assets | 46.6% | 32.3% | 38% |
|
| F-Score | 3 | 3 | 18% |
|
Citius Pharmaceuticals, Inc. did not pass any screens on 10/23/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
